{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024560","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.248617+00:00","generated_at":"2026-06-21T23:32:22.986376+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Revelation Biosciences Q3 2022 net loss $1.2M; cash $6.2M, expects runway through June 2023","bullets":["Net loss Q3 2022 $1.2M ($0.06/share) vs $3.0M ($0.48/share) in Q3 2021.","Cash $6.2M at Sep 30, 2022, up from $1.3M at Dec 31, 2021; expects to fund ops through June 2023.","Completed a $5.0M public offering.","Licensed Vanderbilt IP for REVTx-100; positive preclinical data for REVTx-300 in acute kidney injury.","Anticipates starting Phase 1a clinical study for REVTx-100 and REVTx-300."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024560","json":"https://secwatch.observer/filing/0000950170-22-024560.json","markdown":"https://secwatch.observer/filing/0000950170-22-024560.md","text":"https://secwatch.observer/filing/0000950170-22-024560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/revb-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:32:22.986376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"570c4cc752e5a9a6fc5188e5349d6ac9face4021","claim":"REVELATION BIOSCIENCES, INC. reported the nine months ended September 30, 2022 results: net income $9.6 million, EPS $0.57 per share.","evidence_excerpt":"Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"$9.6 million"},{"label":"EPS","value":"$0.57 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cff12e9ee47c6be45c66aee2d834d48d51255ed7","claim":"REVELATION BIOSCIENCES, INC. reported the three months ended September 30, 2022 results: net income $1.2 million, EPS $0.06 per share.","evidence_excerpt":"Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$1.2 million"},{"label":"EPS","value":"$0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}